Skip to main content
Erschienen in: Journal of Thrombosis and Thrombolysis 1/2012

01.01.2012

Thrombolytic effects of a combined therapy with targeted microbubbles and ultrasound in a 6 h cerebral thrombosis rabbit model

verfasst von: Shu-Ting Ren, Li-Hui Long, Mei Wang, Yi-Ping Li, Hao Qin, Hui Zhang, Bo-Bin Jing, Ying-Xue Li, Wei-Jin Zang, Bing Wang, Xin-Liang Shen

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Our previous study has shown that P1 polypeptide-loaded microbubbles (clot-targeted microbubbles, TMB) are effective for thrombolysis and recanalization in a 0.5 h cerebral thrombosis rabbit model when combined with low-frequency ultrasound (LFUS, 0.8 MHz). However, the thrombolytic effects of TMB combined with LFUS are still unclear in a 6 h cerebral thrombosis rabbit model, which closely resembles human embolic stroke. Aiming to extend the 3 h therapeutic window limitation of thrombolytic drugs, a 6 h cerebral thrombosis model of common carotid artery (CCA) occlusion was induced in rabbits, and thrombolysis using TMB by intra-arterial (IA) and intravenous (IV) application combined with LFUS was then compared to untargeted microbubbles (UTMB) and recombinant tissue plasminogen activator (rt-PA). The patency score and thrombolysis in brain ischemia (TIBI) in IA TMB combined with LFUS (IA TMB/LFUS) were significantly higher compared to the IA normal saline control with LFUS (IA SC/LFUS) (both P < 0.05) and IA UTMB plus LFUS (IA UTMB/LFUS) (both P < 0.05), respectively. The recanalization rate in the IA TMB/LFUS group (66.67%) was significantly higher compared to the IA SC/LFUS group (12.50%, P < 0.05). The patency score, TIBI and recanalization rate of IA TMB/LFUS were higher than in the IV TMB/LFUS group, but there was no significant difference between the two groups, which was similar to the infarction ratio. TMB/LFUS is an effective and safe therapy for thrombolysis in a 6 h cerebral thrombosis rabbit model, and the IA TMB/LFUS group was slightly better than the IV TMB/LFUS group.
Literatur
1.
Zurück zum Zitat Katzan IL, Hammer MD, Hixson ED, Furlan AJ, Abou-Chebl A, Nadzam DM (2004) Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol 61(3):346–350PubMedCrossRef Katzan IL, Hammer MD, Hixson ED, Furlan AJ, Abou-Chebl A, Nadzam DM (2004) Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol 61(3):346–350PubMedCrossRef
2.
Zurück zum Zitat Suzuki Y (2010) Role of tissue-type plasminogen activator in ischemic stroke. J Pharmacol Sci 113(3):203–207PubMedCrossRef Suzuki Y (2010) Role of tissue-type plasminogen activator in ischemic stroke. J Pharmacol Sci 113(3):203–207PubMedCrossRef
3.
Zurück zum Zitat Hamilton A, Huang SL, Warnick D, Stein A, Rabbat M, Madhav T, Kane B, Nagaraj A, Klegerman M, MacDonald R, McPherson D (2002) Left ventricular thrombus enhancement after intravenous injection of echogenic immunoliposomes: studies in a new experimental model. Circulation 105(23):2772–2778PubMedCrossRef Hamilton A, Huang SL, Warnick D, Stein A, Rabbat M, Madhav T, Kane B, Nagaraj A, Klegerman M, MacDonald R, McPherson D (2002) Left ventricular thrombus enhancement after intravenous injection of echogenic immunoliposomes: studies in a new experimental model. Circulation 105(23):2772–2778PubMedCrossRef
4.
Zurück zum Zitat Pieters M, Hekkenberg RT, Barrett-Bergshoeff M, Rijken DC (2004) The effect of 40 kHz ultrasound on tissue plasminogen activator-induced clot lysis in three in vitro models. Ultrasound Med Biol 30(11):1545–1552PubMedCrossRef Pieters M, Hekkenberg RT, Barrett-Bergshoeff M, Rijken DC (2004) The effect of 40 kHz ultrasound on tissue plasminogen activator-induced clot lysis in three in vitro models. Ultrasound Med Biol 30(11):1545–1552PubMedCrossRef
5.
Zurück zum Zitat Hitchcock KE, Holland CK (2010) Ultrasound-assisted thrombolysis for stroke therapy: better thrombus break-up with bubbles. Stroke 41(10 Suppl):S50–S53PubMedCrossRef Hitchcock KE, Holland CK (2010) Ultrasound-assisted thrombolysis for stroke therapy: better thrombus break-up with bubbles. Stroke 41(10 Suppl):S50–S53PubMedCrossRef
6.
Zurück zum Zitat Meunier JM, Holland CK, Pancioli AM, Lindsell CJ, Shaw GJ (2009) Effect of low frequency ultrasound on combined rt-PA and eptifibatide thrombolysis in human clots. Thromb Res 123(3):528–536PubMedCrossRef Meunier JM, Holland CK, Pancioli AM, Lindsell CJ, Shaw GJ (2009) Effect of low frequency ultrasound on combined rt-PA and eptifibatide thrombolysis in human clots. Thromb Res 123(3):528–536PubMedCrossRef
7.
Zurück zum Zitat Pancioli AM, Broderick J, Brott T, Tomsick T, Khoury J, Bean J, del Zoppo G, Kleindorfer D, Woo D, Khatri P, Castaldo J, Frey J, Gebel J Jr, Kasner S, Kidwell C, Kwiatkowski T, Libman R, Mackenzie R, Scott P, Starkman S, Thurman RJ (2008) The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial. Stroke 39(12):3268–3276PubMedCrossRef Pancioli AM, Broderick J, Brott T, Tomsick T, Khoury J, Bean J, del Zoppo G, Kleindorfer D, Woo D, Khatri P, Castaldo J, Frey J, Gebel J Jr, Kasner S, Kidwell C, Kwiatkowski T, Libman R, Mackenzie R, Scott P, Starkman S, Thurman RJ (2008) The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial. Stroke 39(12):3268–3276PubMedCrossRef
8.
Zurück zum Zitat Pancioli AM, Brott TG (2004) Therapeutic potential of platelet glycoprotein IIb/IIIa receptor antagonists in acute ischaemic stroke: scientific rationale and available evidence. CNS Drugs 18(14):981–988PubMedCrossRef Pancioli AM, Brott TG (2004) Therapeutic potential of platelet glycoprotein IIb/IIIa receptor antagonists in acute ischaemic stroke: scientific rationale and available evidence. CNS Drugs 18(14):981–988PubMedCrossRef
9.
Zurück zum Zitat Rebeiz AG, Johanson P, Green CL, Crater SW, Roe MT, Langer A, Giugliano RP, Lincoff AM, Newby LK, Harrington RA, Topol EJ, Califf RM, Wagner GS, Krucoff MW (2005) Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials). Am J Cardiol 95(5):611–614PubMedCrossRef Rebeiz AG, Johanson P, Green CL, Crater SW, Roe MT, Langer A, Giugliano RP, Lincoff AM, Newby LK, Harrington RA, Topol EJ, Califf RM, Wagner GS, Krucoff MW (2005) Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials). Am J Cardiol 95(5):611–614PubMedCrossRef
10.
Zurück zum Zitat Tepe G, Schott U, Erley CM, Albes J, Claussen CD, Duda SH (1999) Platelet glycoprotein IIb/IIIa receptor antagonist used in conjunction with thrombolysis for peripheral arterial thrombosis. AJR Am J Roentgenol 172(5):1343–1346PubMed Tepe G, Schott U, Erley CM, Albes J, Claussen CD, Duda SH (1999) Platelet glycoprotein IIb/IIIa receptor antagonist used in conjunction with thrombolysis for peripheral arterial thrombosis. AJR Am J Roentgenol 172(5):1343–1346PubMed
11.
Zurück zum Zitat Alonso A, Della Martina A, Stroick M, Fatar M, Griebe M, Pochon S, Schneider M, Hennerici M, Allemann E, Meairs S (2007) Molecular imaging of human thrombus with novel abciximab immunobubbles and ultrasound. Stroke 38(5):1508–1514PubMedCrossRef Alonso A, Della Martina A, Stroick M, Fatar M, Griebe M, Pochon S, Schneider M, Hennerici M, Allemann E, Meairs S (2007) Molecular imaging of human thrombus with novel abciximab immunobubbles and ultrasound. Stroke 38(5):1508–1514PubMedCrossRef
12.
Zurück zum Zitat Schumann PA, Christiansen JP, Quigley RM, McCreery TP, Sweitzer RH, Unger EC, Lindner JR, Matsunaga TO (2002) Targeted-microbubble binding selectively to GPIIb IIIa receptors of platelet thrombi. Invest Radiol 37(11):587–593PubMedCrossRef Schumann PA, Christiansen JP, Quigley RM, McCreery TP, Sweitzer RH, Unger EC, Lindner JR, Matsunaga TO (2002) Targeted-microbubble binding selectively to GPIIb IIIa receptors of platelet thrombi. Invest Radiol 37(11):587–593PubMedCrossRef
13.
Zurück zum Zitat Unger E, Metzger P III, Krupinski E, Baker M, Hulett R, Gabaeff D, Mills J, Ihnat D, McCreery T (2000) The use of a thrombus-specific ultrasound contrast agent to detect thrombus in arteriovenous fistulae. Invest Radiol 35(1):86–89PubMedCrossRef Unger E, Metzger P III, Krupinski E, Baker M, Hulett R, Gabaeff D, Mills J, Ihnat D, McCreery T (2000) The use of a thrombus-specific ultrasound contrast agent to detect thrombus in arteriovenous fistulae. Invest Radiol 35(1):86–89PubMedCrossRef
14.
Zurück zum Zitat Wang B, Zang WJ, Wang M, Ai H, Wang YW, Li YP, He GS, Wang L, Yu XJ (2006) Prolonging the ultrasound signal enhancement from thrombi using targeted microbubbles based on sulfur-hexafluoride-filled gas. Acad Radiol 13(4):428–433PubMedCrossRef Wang B, Zang WJ, Wang M, Ai H, Wang YW, Li YP, He GS, Wang L, Yu XJ (2006) Prolonging the ultrasound signal enhancement from thrombi using targeted microbubbles based on sulfur-hexafluoride-filled gas. Acad Radiol 13(4):428–433PubMedCrossRef
15.
Zurück zum Zitat Wang B, Wang L, Zhou XB, Liu YM, Wang M, Qin H, Wang CB, Liu J, Yu XJ, Zang WJ (2008) Thrombolysis effect of a novel targeted microbubble with low-frequency ultrasound in vivo. Thromb Haemost 100(2):356–361PubMed Wang B, Wang L, Zhou XB, Liu YM, Wang M, Qin H, Wang CB, Liu J, Yu XJ, Zang WJ (2008) Thrombolysis effect of a novel targeted microbubble with low-frequency ultrasound in vivo. Thromb Haemost 100(2):356–361PubMed
16.
Zurück zum Zitat Zhou XB, Qin H, Li J, Wang B, Wang CB, Liu YM, Jia XD, Shi N (2011) Platelet-targeted microbubbles inhibit re-occlusion after thrombolysis with transcutaneous ultrasound and microbubbles. Ultrasonics 51(3):270–274PubMedCrossRef Zhou XB, Qin H, Li J, Wang B, Wang CB, Liu YM, Jia XD, Shi N (2011) Platelet-targeted microbubbles inhibit re-occlusion after thrombolysis with transcutaneous ultrasound and microbubbles. Ultrasonics 51(3):270–274PubMedCrossRef
17.
Zurück zum Zitat Kirchhof K, Welzel T, Zoubaa S, Lichy C, Sikinger M, de Ruiz HL, Sartor K (2002) New method of embolus preparation for standardized embolic stroke in rabbits. Stroke 33(9):2329–2333PubMedCrossRef Kirchhof K, Welzel T, Zoubaa S, Lichy C, Sikinger M, de Ruiz HL, Sartor K (2002) New method of embolus preparation for standardized embolic stroke in rabbits. Stroke 33(9):2329–2333PubMedCrossRef
18.
Zurück zum Zitat Xie F, Tsutsui JM, Lof J, Unger EC, Johanning J, Culp WC, Matsunaga T, Porter TR (2005) Effectiveness of lipid microbubbles and ultrasound in declotting thrombosis. Ultrasound Med Biol 31(7):979–985PubMedCrossRef Xie F, Tsutsui JM, Lof J, Unger EC, Johanning J, Culp WC, Matsunaga T, Porter TR (2005) Effectiveness of lipid microbubbles and ultrasound in declotting thrombosis. Ultrasound Med Biol 31(7):979–985PubMedCrossRef
19.
Zurück zum Zitat Henninger N, Kumar R, Fisher M (2010) Acute ischemic stroke therapy. Expert Rev Cardiovasc Ther 8(10):1389–1398PubMedCrossRef Henninger N, Kumar R, Fisher M (2010) Acute ischemic stroke therapy. Expert Rev Cardiovasc Ther 8(10):1389–1398PubMedCrossRef
20.
Zurück zum Zitat Wu TC, Grotta JC (2010) Stroke treatment and prevention: five new things. Neurology 75(18 Suppl 1):S16–S21PubMedCrossRef Wu TC, Grotta JC (2010) Stroke treatment and prevention: five new things. Neurology 75(18 Suppl 1):S16–S21PubMedCrossRef
21.
Zurück zum Zitat Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Callahan F, Clark WM, Silver F, Rivera F (1999) Intra-arterial prourokinase for acute ischemic stroke The PROACT II study: a randomized controlled trial Prolyse in Acute Cerebral Thromboembolism. JAMA 282(21):2003–2011PubMedCrossRef Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Callahan F, Clark WM, Silver F, Rivera F (1999) Intra-arterial prourokinase for acute ischemic stroke The PROACT II study: a randomized controlled trial Prolyse in Acute Cerebral Thromboembolism. JAMA 282(21):2003–2011PubMedCrossRef
22.
Zurück zum Zitat Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D (2008) Thrombolysis with alteplase 3 to 4.5 h after acute ischemic stroke. N Engl J Med 359(13):1317–1329PubMedCrossRef Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D (2008) Thrombolysis with alteplase 3 to 4.5 h after acute ischemic stroke. N Engl J Med 359(13):1317–1329PubMedCrossRef
23.
Zurück zum Zitat Abou-Chebl A (2010) Endovascular treatment of acute ischemic stroke may be safely performed with no time window limit in appropriately selected patients. Stroke 41(9):1996–2000PubMedCrossRef Abou-Chebl A (2010) Endovascular treatment of acute ischemic stroke may be safely performed with no time window limit in appropriately selected patients. Stroke 41(9):1996–2000PubMedCrossRef
24.
Zurück zum Zitat Flores R, Hennings LJ, Lowery JD, Brown AT, Culp WC (2011) Microbubble-augmented ultrasound sonothrombolysis decreases intracranial hemorrhage in a rabbit model of acute ischemic stroke. Invest Radiol Flores R, Hennings LJ, Lowery JD, Brown AT, Culp WC (2011) Microbubble-augmented ultrasound sonothrombolysis decreases intracranial hemorrhage in a rabbit model of acute ischemic stroke. Invest Radiol
25.
Zurück zum Zitat Deshmukh VR, Fiorella DJ, Albuquerque FC, Frey J, Flaster M, Wallace RC, Spetzler RF, McDougall CG (2005) Intra-arterial thrombolysis for acute ischemic stroke: preliminary experience with platelet glycoprotein IIb/IIIa inhibitors as adjunctive therapy. Neurosurgery 56(1):46–54 (discussion 54-45)PubMed Deshmukh VR, Fiorella DJ, Albuquerque FC, Frey J, Flaster M, Wallace RC, Spetzler RF, McDougall CG (2005) Intra-arterial thrombolysis for acute ischemic stroke: preliminary experience with platelet glycoprotein IIb/IIIa inhibitors as adjunctive therapy. Neurosurgery 56(1):46–54 (discussion 54-45)PubMed
26.
Zurück zum Zitat Ammi AY, Mast TD, Huang IH, Abruzzo TA, Coussios CC, Shaw GJ, Holland CK (2008) Characterization of ultrasound propagation through ex vivo human temporal bone. Ultrasound Med Biol 34(10):1578–1589PubMedCrossRef Ammi AY, Mast TD, Huang IH, Abruzzo TA, Coussios CC, Shaw GJ, Holland CK (2008) Characterization of ultrasound propagation through ex vivo human temporal bone. Ultrasound Med Biol 34(10):1578–1589PubMedCrossRef
27.
Zurück zum Zitat Schneider F, Gerriets T, Walberer M, Mueller C, Rolke R, Eicke BM, Bohl J, Kempski O, Kaps M, Bachmann G, Dieterich M, Nedelmann M (2006) Brain edema and intracerebral necrosis caused by transcranial low-frequency 20-kHz ultrasound: a safety study in rats. Stroke 37(5):1301–1306PubMedCrossRef Schneider F, Gerriets T, Walberer M, Mueller C, Rolke R, Eicke BM, Bohl J, Kempski O, Kaps M, Bachmann G, Dieterich M, Nedelmann M (2006) Brain edema and intracerebral necrosis caused by transcranial low-frequency 20-kHz ultrasound: a safety study in rats. Stroke 37(5):1301–1306PubMedCrossRef
28.
Zurück zum Zitat Ding ZT, Yao JL, Zhu GX, Su MF (1999) Delayed UK therapy in a rabbit model of thromboembolic stroke. J Brain Nerves Dis 7(5):264–267 (Chinese) Ding ZT, Yao JL, Zhu GX, Su MF (1999) Delayed UK therapy in a rabbit model of thromboembolic stroke. J Brain Nerves Dis 7(5):264–267 (Chinese)
Metadaten
Titel
Thrombolytic effects of a combined therapy with targeted microbubbles and ultrasound in a 6 h cerebral thrombosis rabbit model
verfasst von
Shu-Ting Ren
Li-Hui Long
Mei Wang
Yi-Ping Li
Hao Qin
Hui Zhang
Bo-Bin Jing
Ying-Xue Li
Wei-Jin Zang
Bing Wang
Xin-Liang Shen
Publikationsdatum
01.01.2012
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 1/2012
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-011-0644-z

Weitere Artikel der Ausgabe 1/2012

Journal of Thrombosis and Thrombolysis 1/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Hereditäres Angioödem: Tablette könnte Akuttherapie erleichtern

05.06.2024 Hereditäres Angioödem Nachrichten

Medikamente zur Bedarfstherapie bei hereditärem Angioödem sind bisher nur als Injektionen und Infusionen verfügbar. Der Arzneistoff Sebetralstat kann oral verabreicht werden und liefert vielversprechende Daten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.